Investors
Quarterly Reports
Q3 2020 Report
Tuesday, 17 NovemberOnlineWebcast link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20201117_1
Dial-in numbers:
NO: +47-21-956342
SE: +46-4-0682-0620
DK: +45 78768490
UK: +44-203-7696819
US: +1 646-787-0157
Pin: 712491
Link to live webcastScientific Presentations
ASH 2020, Prof. Sonja Loges et al.
6 December 2020
A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab, in pts with previouslytreated advanced NSCLC: Updated clinical & translational analysis
Read More
Annual Report 2019
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
Our annual report
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159